Derek Archila
Stock Analyst at Wells Fargo
(4.51)
# 482
Out of 5,182 analysts
235
Total ratings
56.88%
Success rate
19.49%
Average return
Main Sectors:
Stocks Rated by Derek Archila
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Downgrades: Equal-Weight | $26 → $41 | $40.94 | +0.15% | 15 | Apr 17, 2026 | |
| SLNO Soleno Therapeutics | Downgrades: Equal-Weight | $110 → $53 | $52.72 | +0.53% | 5 | Apr 17, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $29 → $28 | $16.68 | +67.87% | 9 | Apr 9, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Equal-Weight | $29 → $20 | $13.73 | +45.67% | 4 | Mar 31, 2026 | |
| ALXO ALX Oncology Holdings | Initiates: Overweight | $5 | $1.67 | +199.40% | 1 | Mar 19, 2026 | |
| GLUE Monte Rosa Therapeutics | Maintains: Overweight | $30 → $29 | $19.79 | +46.54% | 10 | Mar 18, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $136 → $143 | $85.70 | +66.86% | 9 | Mar 12, 2026 | |
| SEPN Septerna | Maintains: Overweight | $28 → $48 | $24.67 | +94.57% | 6 | Mar 3, 2026 | |
| IRON Disc Medicine | Maintains: Overweight | $78 → $79 | $68.85 | +14.74% | 3 | Mar 2, 2026 | |
| ARGX argenx SE | Maintains: Overweight | $1,317 → $1,247 | $780.25 | +59.82% | 16 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $88 → $98 | $73.28 | +33.73% | 3 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $107 → $101 | $94.65 | +6.71% | 13 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $322 → $330 | $229.27 | +43.94% | 16 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $479 → $376 | $305.54 | +23.06% | 2 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $39 | $24.93 | +56.44% | 2 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $33 | $9.06 | +264.24% | 4 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $69 → $116 | $84.91 | +36.62% | 10 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $25 | $10.24 | +144.14% | 2 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $27 | $5.88 | +359.18% | 4 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $10.44 | +43.68% | 8 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $81 | $58.88 | +37.57% | 4 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $36 → $30 | $44.94 | -33.24% | 4 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $7.33 | -31.79% | 12 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $10 | $2.88 | +247.22% | 6 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $25 → $1 | $0.79 | +27.37% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $38 | $33.29 | +14.15% | 4 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $40 → $30 | $33.33 | -9.99% | 1 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $2.95 | -32.20% | 11 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $6 → $5 | $3.98 | +25.63% | 5 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $15 | $6.22 | +141.16% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $14 | $28.10 | -50.18% | 5 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $45 | $28.58 | +57.45% | 9 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $37 → $20 | $1.91 | +947.12% | 7 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.17 | +248.30% | 1 | Aug 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $298 → $193 | $28.64 | +573.88% | 1 | Jul 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 → $41 | $87.50 | -53.14% | 1 | Apr 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $480 → $160 | $14.31 | +1,018.10% | 3 | Mar 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $180 → $60 | $19.79 | +203.18% | 3 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | $29 | $6.89 | +320.90% | 4 | Dec 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $50 | $1.19 | +4,101.68% | 2 | Jun 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $51 | $24.11 | +111.53% | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $88 | $11.82 | +644.50% | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $24.51 | - | 1 | Sep 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $30.64 | - | 2 | Aug 3, 2017 |
Apellis Pharmaceuticals
Apr 17, 2026
Downgrades: Equal-Weight
Price Target: $26 → $41
Current: $40.94
Upside: +0.15%
Soleno Therapeutics
Apr 17, 2026
Downgrades: Equal-Weight
Price Target: $110 → $53
Current: $52.72
Upside: +0.53%
Nurix Therapeutics
Apr 9, 2026
Maintains: Overweight
Price Target: $29 → $28
Current: $16.68
Upside: +67.87%
Viridian Therapeutics
Mar 31, 2026
Maintains: Equal-Weight
Price Target: $29 → $20
Current: $13.73
Upside: +45.67%
ALX Oncology Holdings
Mar 19, 2026
Initiates: Overweight
Price Target: $5
Current: $1.67
Upside: +199.40%
Monte Rosa Therapeutics
Mar 18, 2026
Maintains: Overweight
Price Target: $30 → $29
Current: $19.79
Upside: +46.54%
Rhythm Pharmaceuticals
Mar 12, 2026
Maintains: Overweight
Price Target: $136 → $143
Current: $85.70
Upside: +66.86%
Septerna
Mar 3, 2026
Maintains: Overweight
Price Target: $28 → $48
Current: $24.67
Upside: +94.57%
Disc Medicine
Mar 2, 2026
Maintains: Overweight
Price Target: $78 → $79
Current: $68.85
Upside: +14.74%
argenx SE
Feb 27, 2026
Maintains: Overweight
Price Target: $1,317 → $1,247
Current: $780.25
Upside: +59.82%
Feb 13, 2026
Maintains: Overweight
Price Target: $88 → $98
Current: $73.28
Upside: +33.73%
Feb 11, 2026
Maintains: Equal-Weight
Price Target: $107 → $101
Current: $94.65
Upside: +6.71%
Jan 20, 2026
Maintains: Overweight
Price Target: $322 → $330
Current: $229.27
Upside: +43.94%
Jan 20, 2026
Maintains: Equal-Weight
Price Target: $479 → $376
Current: $305.54
Upside: +23.06%
Jan 6, 2026
Maintains: Overweight
Price Target: $17 → $39
Current: $24.93
Upside: +56.44%
Dec 16, 2025
Maintains: Overweight
Price Target: $31 → $33
Current: $9.06
Upside: +264.24%
Dec 9, 2025
Maintains: Overweight
Price Target: $69 → $116
Current: $84.91
Upside: +36.62%
Dec 8, 2025
Maintains: Overweight
Price Target: $19 → $25
Current: $10.24
Upside: +144.14%
Nov 19, 2025
Maintains: Overweight
Price Target: $14 → $27
Current: $5.88
Upside: +359.18%
Nov 6, 2025
Maintains: Overweight
Price Target: $16 → $15
Current: $10.44
Upside: +43.68%
Nov 5, 2025
Maintains: Overweight
Price Target: $51 → $81
Current: $58.88
Upside: +37.57%
Oct 21, 2025
Maintains: Equal-Weight
Price Target: $36 → $30
Current: $44.94
Upside: -33.24%
Oct 17, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $7.33
Upside: -31.79%
Sep 23, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $2.88
Upside: +247.22%
Sep 16, 2025
Downgrades: Equal-Weight
Price Target: $25 → $1
Current: $0.79
Upside: +27.37%
Aug 20, 2025
Maintains: Overweight
Price Target: $44 → $38
Current: $33.29
Upside: +14.15%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $40 → $30
Current: $33.33
Upside: -9.99%
Aug 8, 2025
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $2.95
Upside: -32.20%
Aug 7, 2025
Maintains: Equal-Weight
Price Target: $6 → $5
Current: $3.98
Upside: +25.63%
Mar 12, 2025
Maintains: Equal-Weight
Price Target: $16 → $15
Current: $6.22
Upside: +141.16%
Dec 19, 2024
Maintains: Equal-Weight
Price Target: $12 → $14
Current: $28.10
Upside: -50.18%
Dec 19, 2024
Maintains: Overweight
Price Target: $47 → $45
Current: $28.58
Upside: +57.45%
May 5, 2021
Downgrades: Hold
Price Target: $37 → $20
Current: $1.91
Upside: +947.12%
Aug 4, 2020
Initiates: Buy
Price Target: $18
Current: $5.17
Upside: +248.30%
Jul 10, 2020
Downgrades: Hold
Price Target: $298 → $193
Current: $28.64
Upside: +573.88%
Apr 15, 2020
Reiterates: Buy
Price Target: $61 → $41
Current: $87.50
Upside: -53.14%
Mar 31, 2020
Maintains: Hold
Price Target: $480 → $160
Current: $14.31
Upside: +1,018.10%
Mar 17, 2020
Downgrades: Hold
Price Target: $180 → $60
Current: $19.79
Upside: +203.18%
Dec 11, 2018
Downgrades: Perform
Price Target: $29
Current: $6.89
Upside: +320.90%
Jun 22, 2018
Maintains: Outperform
Price Target: $34 → $50
Current: $1.19
Upside: +4,101.68%
Nov 15, 2017
Maintains: Outperform
Price Target: $32 → $51
Current: $24.11
Upside: +111.53%
Sep 7, 2017
Initiates: Outperform
Price Target: $88
Current: $11.82
Upside: +644.50%
Sep 7, 2017
Initiates: Market Perform
Price Target: n/a
Current: $24.51
Upside: -
Aug 3, 2017
Downgrades: Perform
Price Target: n/a
Current: $30.64
Upside: -